Efficacy of a spatial repellent for control of malaria in

Indonesia: a cluster-randomized controlled trial

Din Syafruddin[1], Puji BS Asih[1], Ismail Ekoprayitno Rozi[1], Dendi Hadi Permana[1], Anggi Puspa

Nur Hidayati[1], Lepa Syahrani[1], Siti Zubaidah[1], Dian Sidik[2], Michael J. Bangs[3], Claus Bøgh[4],

Fang Liu[5], Evercita C. Eugenio[5], Jared Hendrickson[6], Timothy Burton[7], J. Kevin Baird[8], Frank

Collins[7], John P. Grieco[7], Neil F. Lobo[7±] and Nicole L. Achee[7±]*

[1]Eijkman Institute for Molecular Biology, Jakarta, Indonesia; Department of
Parasitology, Faculty of Medicine, Universitas Hasanuddin, Makassar,
Indonesia;
[2]Department of Epidemiology, Faculty of Public Health, Universitas
Hasanuddin, Makassar, Indonesia
[3]Public Health and Malaria Control, PT Freeport Indonesia, International
SOS, Kuala Kencana, Papua Indonesia;
[4]The Sumba Foundation, Public Health and Malaria Control, Bali,
Indonesia;
[5]Department of Applied Mathematics, University of Notre Dame, Indiana;
[6]Center for Computer Research, University of Notre Dame, Notre Dame,
Indiana;
[7]Department of Biological Sciences, Eck Institute for Global Health,
University of Notre Dame, Notre Dame, Indiana;
[8]Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, and the Centre
for Tropical Medicine, Nuffield Department of Medicine, University of
Oxford, Oxford, United Kingdom;
24
25   [±]Indicates equal seniority
26
27   *Corresponding author:
28
Nicole L. Achee, PhD
Research Professor
Eck Institute for Global Health
Department of Biological Sciences
239 Galvin Life Science Center
Notre Dame, Indiana 46556
Ph: 574.631.1561
Email: nachee@nd.edu
37

Abstract. A cluster randomized, double-blinded, placebo-controlled trial was conducted to

estimate protective efficacy of a spatial repellent against malaria infection at Sumba, Indonesia.

Following radical cure in 1,341 children aged ≥ 6 months - ≤5 years in 24 clusters, households

were given transfluthrin or placebo passive emanators. Monthly blood screening and biweekly

human-landing mosquito catches (HLC) were performed during 10-months baseline (June 2015

to March 2016) and a 24-month intervention period (April 2016 to April 2018). Screening

detected 164 first-time malaria infections and an accumulative total of 459 infections in 667

subjects in placebo-control households; and 134 first-time and 253 accumulative total infections

among 665 subjects in active intervention households. The 24-cluster protective effect of 27.7%

and 31.3%, for time to first-event and overall (total new) infections, respectively, was not

statistically significant. Purportedly, this was likely due in part to zero to low incidence in some

clusters, undermining the ability to detect a protective effect from spatial repellent intervention.

Subgroup analysis of 19 clusters where at least one malaria infection occurred during the

baseline showed 33.3% and 40.9% (statistically significant at 1-sided 5% significance level; *p*

=0.0236) protective effect to first-infection and overall infections, respectively. Among 12

moderate- to high-risk clusters, a statistically significant decrease on infection by the spatial

repellent was detected (60% protective efficacy). Primary entomological analysis of impact was

inconclusive and proved not statistically significant. While this study suggests protective effects

of the intervention, additional evidence is required to demonstrate that spatial repellents provide

an operationally feasible and effective means of reducing malaria transmission.

<u>INTRODUCTION</u>

It has been nearly 75 years since the role of spatial repellency (deterrency or avoidance)

was first described as a potentially beneficial attribute in malaria control, showing chemicals

could effectively disrupt normal host-seeking mosquito behavior and interrupt contact with

humans, thus preventing disease transmission.[1-3] Spatial repellency is used here as a general term

to refer to a range of insect behaviors induced by airborne, volatile chemicals that ultimately

result in a reduction in human-vector contact. These behaviors include movement away from a

treated space with chemical stimulus, interference with host detection (attraction-inhibition)

and/or interference with feeding response (feeding-inhibition).[4-7] Spatial repellency can be

measured and distinguished from other chemical actions, primarily contact irritancy and toxicity,

in the laboratory[8, 9] and in semi-field evaluations.[10, 11] Which behavior is elicited by a volatile

chemical depends on the concentration or dose-exposure interaction by the mosquito in the

treated space. For example, toxicity occurs at higher chemical doses while deterrence (behavioral

avoidance) can result from lower, sub-lethal chemical concentrations.[12] Currently, the majority

of commercial spatial repellent products utilize either low concentrations of short-duration

United States Environmental Protection Agency (USEPA) registered synthetic pyrethroids

(pyrethrin, metofluthrin and more recently transfluthrin)[13] or botanical-based compounds.[14, 15]

The World Health Organization (WHO) Vector Control Advisory Group (VCAG)

assesses evidence on the epidemiological effectiveness of new vector control interventions and

by doing so supports WHO's development of policy recommendations, including the potential

use of spatial repellents as a public health vector control strategy.[16] Reviewed by VCAG since

2014, the assessment of rigorous epidemiological evidence for endorsing a policy

recommendation of a spatial repellent intervention class remains limited and deemed

insufficient.[17] A malaria prevalence study in China evaluating mosquito coils containing 0.03%

transfluthrin demonstrated a 77% reduction in human *Plasmodium falciparum* cases[18] and the

use of coils containing 0.00975% metofluthrin provided 52% protective efficacy (PE) against

new (incident) malaria infections in Indonesia.[19] Although primary outcomes from both studies

were encouraging, neither met the required VCAG evidence for full pubic health assessment

either due to lack of rigor in study design (small cluster number in Indonesia) and/or being

underpowered (both studies).[20] The importance of a WHO policy for implementation of spatial

repellents in malaria control programs could dramatically increase investments by private

industry to develop chemicals that operate through modes of actions to elicit vector behavior

changes other than purely toxicity. This would potentially introduce a new generation of

effective active ingredients and product formulations into the disease control/eradication

arsenal.[21, 22] In combination with existing WHO-recommended malaria control interventions,

spatial repellents have the potential to add significant protective benefit, especially where

traditional long-lasting insecticidal nets (LLINs) or indoor residual spraying (IRS) may not be

sufficiently protective (e.g. early-evening blood feeding vectors when LLINs are not in use

and/or where vectors do not or limit resting time indoors on insecticide-treated surfaces), be

unavailable, or are impractical and/or infeasible (emergency relief operations). Control or

elimination of malaria in these circumstances will require innovative approaches; as example

spatial repellents providing a highly beneficial protective role against transmission.[23, 24]

The current claim of a spatial repellent intervention class for public health value is

'deployment of a spatial repellent will prevent human-vector contact to reduce pathogen

transmission'. The role of spatial repellency in public health is dependent on assessing whether

or not human protection is rigorously evidenced, thus the requirement of clinical trials using a

prototype spatial repellent product for the intervention class. With this epidemiological primary

endpoint in mind, the objectives of the current RCT were to build upon previous epidemiological

findings and provide rigorous evidence of a spatial repellent that provides a sufficient protective

effect against malaria infection risk and demonstrate risk reduction by decreasing relevant

entomological measures (e.g., anopheline human landing (biting) density, age-grading parity

and/or sporozoite infectivity rates) in endemic communities. The rationale for conducting the

RCT at Sumba Island stems from an essential requirement by WHO VCAG that more evidence

of human health impact is needed to recommend a WHO global public health spatial repellent

policy and that such evidence should come from varied malaria endemicity settings (low,

moderate and high).[16] The underlying reason for integrating entomological measures (above) in

the RCT was to identify correlations, if any, with PE which could then be used in future trials

with appropriate minimum thresholds required to demonstrate non-inferiority of next-generation

spatial repellent products.

METHODS

The study was registered in clinicaltrials.gov (Identifier: NCT02294188) and performed

according to The International Conference on Harmonisation's (ICH) Guideline for Good

Clinical Practice (GCP; document E6) (R1) and The OECD Principles of Good Laboratory

Practice (GLP) based on The National Agency of Drug and Food Control, Indonesia regulations.

There were no changes to methods after trial commencement.[25, 26]

Ethics statement. Ethical review and approval for this study was granted by the Ethics

Committee (EC) of the Faculty of Medicine, Universitas Hasanuddin (Protocol #UH14070385),

the University of Notre Dame (Protocol #14-01-1448) and endorsed by the Eijkman Institute

Research Ethics Committee, Jakarta, Indonesia. Consent was obtained from parents or guardians

of child recruits following EC guidelines. For sentinel households participating in entomological

collections, signed consent was sought from the head-of-household. No data on individuals was

collected during the entomological collections. During the consenting process, the study was

described and the relevant consent form read in local dialect by study staff. The consent form

detailed the design of the study including radical cure, the purpose of collecting and storage of

blood samples (towards laboratory-based malaria diagnosis), descriptions of the study risks,

benefits, and procedures of therapeutic radical cure and follow-up. For households recruited for

entomology measures, the consent form detailed the design of mosquito collections and

descriptions of study risks, benefits and procedures of human landing catch (HLC).

Participants who were illiterate were asked to appose their thumbprint and, when

possible, a literate witness was asked to sign (i.e., a witness selected/known by the participant

and having no connection to the research team). All households were provided with a signed

copy of the consent form after agreeing to participate in the study. Adverse events were captured

during participant follow-up and entomological collections and reported to monitoring

authorities in accordance with the approved protocol. All participants were free to drop out of the

study at any time, regardless of reason or having to provide one, and without prejudice.

Study setting. The study was conducted in Southwest and West Sumba districts, East Nusa

Tenggara Province, Indonesia (**Figure 1**). The circa 400,000 residents of the two districts occupy

175 village 'groups' (*desas*) and several small-sized towns.[27] Thirteen village groups, with

resident populations ranging between 1,067 and 3,904 (avg. 2,132), served as study locations for

the final selection of the 24 study clusters consisting of multiple desas. Organized bed net

campaigns were recently introduced with the last mass distribution occurring in February-March

2018 across the study area. A mass distribution of long-lasting insecticidal nets (LLINs) occurred

in October-December 2014 in both districts (Olyset Net® (Olyset Net®, permethrin 2.0% w/w)

with a reported > 95% coverage of households provided 1-4 nets each. A second round of LLIN

mass distribution occurred February-March 2018 (PermaNet® 3.0, deltamethrin 180mg/m2 +

PBO synergist). The last round of focal IRS occurred in 2003 using a pyrethroid-based product.

The malaria prevalence based on microscopically diagnosed parasitemia drawn from a random

sample of 50% of residents present in 13 villages conducted in 2015, 10 months before the

intervention trial, averaged 15.5% (2.5% to 37.3%) (**Table 1**).

Although very little detail is known about the malaria vector distribution and bionomics

in this study area,[28] an earlier (August 2007) entomologic survey documented 13 species of

anophelines occurring in West Sumba district: *Anopheles aconitus* (Dönitz)*, Anopheles annularis*

Van der Wulp, *Anopheles barbirostris* s.l. (Satoto)*, Anopheles flavirostris* (Ludlow)*, Anopheles*

hyrcanus group (Reid)*, Anopheles indefinitus* (Ludlow)*, Anopheles kochi* (Dönitz)*, Anopheles*

leucosphyrus group (Reid), *Anopheles maculatus* Theobald*, Anopheles subpictus* s.l. Grassi*,*

Anopheles sundaicus s.l. (Dusfour et al.)*, Anopheles tessellatus* Theobald*,* and *Anopheles vagus*

Dönitz.[29] These species vary spatially in relative abundance associated with presence of their

preferred aquatic larval habitats ranging from coastal brackish and freshwater marshes and

ponds, seasonally productive rice paddies, to forested hillsides with perennial running streams

and small rivers. At the time of the survey, human-landing collections revealed *An. subpictus* and

An. vagus as the predominant species in the upland interior locations, and *An. sundaicus* as the

most common species attracted to human along the coastal plain. The majority of residents in

study villages work as small-holder agriculturalist pursuits, typically lacking public supplied

electricity or articulated water supply systems. Homes are predominately traditional designed,

large, thatched-roof structures raised ~1m above ground, averaging ~70 m^3 in size (6 m length x

6 m width x 2 m in height) and constructed with gaping bamboo walls and flooring that offer

little protection from mosquito entry (**Figure 2**).

Trial design. The study was a randomized cluster, double-blind, placebo-controlled, clinical trial

with a total of 24 clusters divided into 12 clusters per intervention arm. The primary outcome of

the study was to demonstrate and quantify the protective efficacy (PE) of a spatial repellent

product in reducing the incidence of malaria infection in a human cohort. The null hypothesis

was that there is no difference in malaria incidence between intervention and control arms.

Clusters were selected based on housing type, focusing on traditional houses (with or without

thatch roofing) (**Figure 2**), mitigation of potential chemical dispersion 'spillover' effect (i.e.,

distance between nearest homes in different clusters ~500 m apart), and logistical considerations

(i.e., distance from field-based satellite laboratories). About fifty-four households were recruited

within each cluster based on human sample size requirements. Households from 13 villages were

stratified into 24 clusters before randomization: Gaura (pop. 2,831; houses 432), Kahale (pop.

3,904, houses 253), Karang Indah (pop. 1,169, houses 139), Manutoghi (pop. 1,067; houses 165),

Matakapore (pop. 2,805; houses 209), Panenggo Ede (pop. 1,271; houses 90), Rada Malando

(pop. 1,842; houses 133), Tana Mete (pop. 2,124; houses 213), Waikarara (pop. 2,709; houses

446), Wailangira (pop. 1,878; houses 226), Waimakaha (pop. 2,334; houses 211), Waimaringi

(pop. 2,598; houses 116), and Weetana (pop. 2,670; houses 275) (**Figure 3**).

Sample size. Previous malaria incidence rates collected in a portion of the study area in coastal

Kodi Subdistrict were used to estimate the likely malaria attack rate in the current study villages

at 0.3 infections/person-year.[19] Sample size determination was based on the hazard rate

comparison in the proportional hazards regression model.[30] The required number of first-time

infections was estimated at 417 to permit detection of a 30% protective effect by the spatial

repellent intervention compared to placebo with 80% power at the type-I error rate, assuming a

between-cluster coefficient of variation (CV) of 30% and a baseline hazard rate of 0.3 per

person-year. With 12 clusters per treatment arm (active or placebo), with 2-month accrual and 22

months follow-up, and an estimated 20% loss-to-follow-up (LTFU) during intervention, a total

of 54 subjects per cluster was required (n=1,296). As entomology measures were used in

relationship analyses of PE rather than hypothesis testing, sample size was based on field

logistical capacity and not for statistical power.

Participants. The average number of children ≤5 years of age in each cluster was 68 (57-79).

From individual households in study clusters, one child, aged ≥6 months - ≤5 years at time of

recruitment, were provided the opportunity to enroll as subjects in the study. Following informed

consent, medical screening consisted of physical examination by a study physician and a

qualitative NADPH spot test for G6PD deficiency (Trinity Biotech qualitative G6PD assayTM,

ref 345-UV, Trinity Biotech, St. Louis, MO).[31] Additional to being G6PD normal status,

eligibility requirements included a bodyweight ≥ 40 kg, hemoglobin > 5mg/dL (Hb201+,

HemoCue AB, Angelholm, Sweden),[32] no severe acute illness/infection on the day of inclusion,

temperature ≤ 38°C, participant acknowledging sleeping in the village > 90% of nights during

220 any given month, not participating in another clinical trial, and with no intensions for extended

221 travel during the study period.

223 **Intervention.** Immediately after completion of radical cure, intervention was simultaneously

224 initiated in all subject households and non-subject households that consented to receive

225 intervention. The spatial repellent intervention is a transfluthrin-based passive emanator

226 produced by S.C. Johnson & Son, Inc (SCJ) designed to release a volatile chemical into the air

227 and prevent human–vector contact by disrupting normal behavior of mosquitoes within the

228 treated space. The indoor placement of the intervention product was designed with the objective

229 to measure PE under indoor use conditions. Transfluthrin is a registered compound commonly

230 found in commercially available mosquito coils globally based on WHO specifications.[33] The

231 U.S. Environmental Protection Agency (EPA) has recently approved transfluthrin products for

232 indoor use with the USA.[34] Emanators (active and placebo) of identical packaging and color

233 were distributed by study personnel every 2 weeks at the individual household application rate of

234 2 units / 9m^2 according to SCJ specifications. There was a median of 1 room (range 1,9) and 10

235 emanators (range 4,56) per household. Intervention devices were positioned indoors by hanging

236 individual emanators on two metal hooks specially attached to walls for this study. Each position

237 remained static throughout the study. The hooks facilitated stabilization of the interventions so

238 the chemical-treated surface was consistently exposed facing the interior space. Research staff

239 placed, removed and replaced emanators in households at set intervals and recorded attrition,

240 based on number of products removed from each structure during each replacement period, to

241 ascertain application rate for use in estimating cluster coverage. During the trial period, quality

242 control analysis was performed by Ross Laboratories, India on unused (in storage) emanators to

verify amount of transfluthrin in actives and the absence of transfluthrin in placebos. At the end

of follow-up period (April 2018), used, unused and expired emanators were disposed of by PT.

Wahana Pamunah Limba Industri in Jakarta according to Indonesian regulations on disposal

requirements.

Randomization, allocation and blinding. Clusters were allocated to receive either active or

placebo treatment using a random number generator (https://www.random.org). The cluster

allocation code was made available from the intervention manufacturer to the Data Safety

Monitoring Board (DSMB) for use in safety assessments. The site database manager assigned a

unique identification number to each household (HIN) and the site intervention administrator

coordinated distribution of blinded active or placebo to enrolled households within each cluster

corresponding to the pre-labeled package code. Unblinded assignments were shared with a site

administrator in a sealed envelope placed in a secure location within the managing center of the

research project (Jakarta) for purposes of emergency unblinding related to adverse and serious

adverse events. Thus, the investigators, research team, study subjects, and residents were blinded

as to which cluster received active versus placebo devices until after completion of the study.

Procedures.

Radical cure and follow-up. **Figure 4** summarizes screening, enrollment, and follow-up of the

incidence density cohorts. A total of 1,353 subjects were presumptively radically treated using a

fixed combination formulation of dihydroartemisinin (DHA)-piperaquine (P) (containing 40 mg

dihydroartemisinin and 320 mg piperaquine (Zhejiang Holley Nanhu, Beijing Holley Cotec)

administered as a weight per dose regimen of 2.25 and 18 mg/kg per dose of dihydroartemisinin

and piperaquine, respectively, once daily for 3 days. Primaquine (PT, Pharos Tbk, Semarang,

Indonesia) 0.25 mg/kg body weight was prescribed for the 14 days immediately before

implementing intervention. The DHA-P combination is currently the first-line antimalarial drug

for uncomplicated malaria treatment in Indonesia. All subjects were examined for *Plasmodium*

spp. infection by expert microscopy, and later confirmed using polymerase chain reaction (PCR)

from matched filter paper blood spot samples.[35] New malaria infections among the participants

were monitored every 4 weeks using microscopic examination of Giemsa-stained blood films

according to WHO guidelines based on a minimum of 200 high magnification (1000x oil-

immersion) thick blood film fields.[36] Two certified expert microscopists independently (blinded)

examined slides on-site at project-dedicated field laboratories. PCR detection of parasite DNA

was conducted at the Eijkman Institute for Molecular Biology (EIMB) central laboratory in

Jakarta for all four *Plasmodium* species.[35] A blood sample was defined as malaria 'positive' for

inclusion in incidence analyses if meeting criteria of having two diagnostic outcomes indicating

presence of parasite (e.g., 2x microscopy; 1x microscopy + 1x PCR; or 2x PCR). All positive

and 10% randomly selected negative samples diagnosed at EIMB were re-tested at the

University of Notre Dame. Discordant microscopy and PCR results required reexamination of

both initial findings. Participants found malaria infected at point-of-care were immediately

treated with DHA-P and were removed from contributing further to person-time at risk of first-

time infection; however, they remained in the study to monitor cumulative incidence for analyses

of overall (total new) infections and estimate number of cases averted.

Entomologic surveys. In a subset of 12 clusters, adult mosquito diversity and densities were

measured using human-landing catches (HLC) every two weeks from start of baseline through

end of follow-up period in a subset of 12 clusters. Clusters for entomological sampling were

selected based on exhibiting highest HLC densities during baseline sampling, along with

existence of mosquito larval habitats. The 12 clusters were hierarchically stratified on criteria of

baseline human landing catch then blindly allocated to treatment arm to ensure a balanced

recruitment (6 clusters in each treatment group). Four neighboring sentinel houses within each of

the 12 clusters were randomly selected for mosquito collections (n=48). Collections were

conducted at sentinel houses for 1 night every 2 weeks from paired active/placebo clusters (e.g.,

3 pairs on Monday night and 3 pairs on Wednesday night) during intervention. Teams of two

collectors were assigned per house, one positioned indoors near the center of the house and one

located outside on the house verandah, approximately 1 m from the exterior wall. Collectors

removed all mosquitoes landing on their exposed lower legs using a mouth aspirator. Collections

were conducted from 1800 to 0600 h for 50 min every hour. Paired collectors rotated between

indoor and outdoor positions each hour. Samples were placed into individual holding containers

labeled by collection hour, unique house code (linked to blinded treatment code), and collection

location (indoor or outside). Captured mosquitoes were immediately killed by ether-soaked

cotton pads in the field and initially identified to species (or species complex) using

morphological characters.[37] All specimens were transported to an on-site base laboratory upon

completion of the 12 h collection and a random sample of representative anopheline species (up

to 20% per cluster per indoor/outdoor location and hour of collection) were dissected for parity

and scored as either gravid/parous or nulliparous.[38] Partial (head-thorax for those dissected for

parity) or whole anopheline specimens were placed singly into individual Eppendorf® 1.5ml

vials and stored over silica gel desiccant until further processing at EIMB, Jakarta, for detection

of malaria sporozoites and molecular-based species identification, where applicable.[39, 40]

Mosquito samples were evaluated for *Plasmodium* species infection using polymerase chain

reaction (PCR) methodologies to derive corresponding malaria sporozoite infection rates by

parasite and vector species.[41] Together with time-adjusted HLC densities (anophelines/person-

night), matched sporozoite rates were used to derive the entomological inoculation rates (EIRs)

for each treatment arm.[42] Anopheline species identification was verified at the University of

Notre Dame following previous protocols (not reported herein).[39, 40]

Insecticide susceptibility assays. Permethrin was evaluated using the WHO standard tube and

CDC bottle assay during baseline, intervention and post-intervention periods at the WHO

recommended discriminating concentration for anophelines 0.75% and CDC recommended dose

21.5µg/ml active ingredient.[40, 41] Both WHO tube assays and CDC bottle assays were

performed on F0 mixed anopheline species collected as immatures in 13 of the 24 study clusters

from across 23 habitat locations during baseline, intervention and 6-mo post-intervention period

(ending Oct 2018). Assays were conducted using non-bloodfed, 3-5 day old females according to

established guidelines.[43, 44] After each test period, all chemical and control specimens were

stored individually over silica gel for analysis at EIMB to confirm species identification and for

detection of target-site mechanisms (e.g., *kdr* gene mutations) of resistance (not reported herein).

Monitoring of adverse events (AE) and serious adverse events (SAE). AEs, possibly related to

transfluthrin exposure, in subjects and other household members, were captured by the study

team during both active and passive blood sampling using a standardized survey form.

Investigation of study-related AEs was performed by the on-site study clinician. SAEs were also

recorded according to protocol, regardless of possible relationship to intervention. Government

clinic health records were compiled on a quarterly basis starting in December 2017 for DSMB

safety assessment of the study population.

Data management and verification. Data collection was designed around a tablet-based survey

platform linked to a custom-built database and web portal. CommCare (Dimagi Inc, MA, USA)

was selected as the frontend form application, providing critical capabilities, including: a parent-

child case structure, the ability to store forms when offline, update form versions after

deployment, build forms with complex logic in a web browser, and export form data to other

tools. Data was cleaned according to rules specified in the study protocol to ensure data

integrity. Study data related to participating subjects and households, intervention

(placement/replacement activity), mosquitoes collected, and lab analyses was cross-checked,

identifying missing, incomplete, or suspect data submissions. These data were relayed to the site

data manager to be resubmitted or corrected. Once data correction was complete, data was

verified and requested for analyses.

Outcomes and statistical methods (S1. Statistical Analyses Plan). The *primary endpoint* for

estimating the protective efficacy (PE) of the spatial repellent intervention was malaria incidence

(time to first infection) among study participants in each of the 24 clusters. All participants, living

in separate households, received a directly observed, presumptive radical cure over a 14-day period

to clear them of any standing (patent, sub-patent, or latent) malaria infections. Subsequent

biweekly blood film examinations were conducted from subjects reporting fever within the

previous 48 hours (active case detection) with routine screening for malaria infection in all subjects

(passive case detection) occurring every 4 weeks for the duration of the study. Study participants

were excluded from analyses when lacking a blood sample during the intervention period or when

a household might have contributed more than two subjects. In the latter case, this occurred (rarely)

when there was loss-to-follow-up (LTFU) on the first recruited subject and a second subject was

recruited as a replacement; only the subject with a longer follow-up period was used based on per-

protocol allowing only one subject per household.

The *primary hypothesis* on PE against first-time malaria infection was tested by comparing

the hazard rates of the first-time malaria infection between active and placebo (blank) intervention.

The complementary log-log (cloglog) regression model $\log(-\log(1 - \theta_{ijt})) = \beta_{0t} + x_{ijt}^t \beta +$

z_i was.[45-48] θ_{ijt} is the discrete time hazard rate of subject j in cluster I at time t, x_{ijt} contains visit

(as a categorical predictor), the individual-level (age, gender), household-level (number of doors,

open eaves Y or N, wall type), and cluster-level (baseline incidence rate, cluster population size,

intervention group) covariates, and $z_i \sim N(0, \sigma^2)$ is the cluster-level random effect.   PE was

estimated by $((1 - \exp(\hat{\beta}))100\%$ with a 90% confidence interval (CI) based on the Wald test,

where $\hat{\beta}$ is the estimated regression coefficient associated with the intervention group, and $\exp(\hat{\beta})$

is the estimated hazard ratio (HR) between active and placebo. The null hypothesis that PE is 0

was tested by the Wald's test $z = \hat{\beta}/s$,, where s is the estimated standard error of $\hat{\beta}$. It was

concluded that active intervention reduces the first-time malaria hazard rate compared to placebo

if $z < z_{0.05} = -1.645$; otherwise, the study would not have sufficient evidence to suggest that

active intervention reduces the first-time malaria hazard rate compared to placebo at a one-sided

significance level of 5%. The Kaplan-Meier (KM) curves on time to first infection per cluster was

provided for the active and placebo arms, respectively.

The statistical analysis of *the secondary endpoint* of the overall (total new) malaria

infections detected in study subjects was similar to that used for analyzing the primary endpoint

of the first-time malaria infection except that the above cloglog model has additional term $z_{j(i)}$,

which is the random effect at the individual level to account for the dependence among multiple

malaria infections per individual. The same set of analyses as described above were performed in

a subgroup analysis in clusters with non-zero baseline incidence rates and those clusters with

entomology data.

The effects of active intervention on the *secondary entomological endpoints* were

estimated using a negative binomial regression model, if applicable. Specifically, the *anopheline*

landing rate (surrogate 'bite' based on HLC and indicator of human-vector contact) is defined as

the number of mosquitos captured during a 12-hr evening interval (1800-0600)**.** The covariates in

the model include the fixed effects of intervention group, the interaction between treatment and

location of collection (inside or outside), visit (as categorical), baseline incidence rate, baseline

vector count, cluster population, and random effects for household nested within cluster and for

cluster. The percentage change in human landing rate by intervention was estimated from the

model. The frequencies and percentages of captured anophelines were also summarized by species.

The set of covariates in the model for analyzing the *parity rate* are similar to the landing rate

model, with an additional offset term for the daily landing rate. Due to data sparsity for the

sporozoite positivity rate (> 99% of tested mosquitos were uninfected), no model-based analysis

was performed and only summary statistics are provided. The *entomological inoculation rate*

(EIR) is defined as the number of malaria infective mosquito bites a person receives per a unit time

(typically annually) and calculated as EIR = sporozoite positivity rate × human biting rate. The

observed data sparsity experienced with low sporozoite positivity also impacts the EIR results, and

thus only summary statistics are provided for EIR.

LLIN usage, measured from responses to the question: *"Did you use a bed net last night?"*

was included as a covariate in the model for PE as a supplementary output.

RESULTS

Protective effect against malaria infection (pre-planned).

Trial outcomes show baseline covariates regarding subject, house construction,

population and baseline malaria incidence between the active and placebo arms were balanced at

the individual-, household-, and cluster-level in the all 24 cluster analyses (**Table 2**). The

intervention coverage rate, defined as the proportion of actually placed emanators over the total

number required per household, ranged from 82.2% to 98.6% by cluster over the entire

intervention period, with a mean application rate of 93.2% and 92.3% for the active and placebo

arms, respectively. The percent of LLIN usage per household during the trial, defined as

responding 'Yes' to the question: *"Did you use a bed net last night?"*, ranged from 14.6% to

99.8% in clusters that received active intervention and 17.4% to 99.8% in clusters that received

placebo (**S2. LLIN Usage**).

There were 134 first-time infections among 665 subjects in active intervention

households and 164 first-time infections in 667 subjects in placebo-control households, with a

27.7% decrease in the first-time malaria hazard risk using active compared with placebo (90%

CI: -21.3%, 56.9%) (**Table 3**). The 27.7% PE was not statistically significant at the 5% one-

sided significance level ($p = 0.151$). The estimated PE of active intervention against overall

(total) malaria infections (first and subsequent) was 31.3% (90% CI: -10.8, 57.4%) with a one-

sided *p*-value = 0.098 (**Table 3**). Investigation of potential shift in parasite species infection

frequency (*P. falciparum* vs. *P. vivax*) between active and placebo arms will be reported in

subsequent publications.

A total of 164 first-time malaria infections occurred during approximately 1032 person-

years at risk in study participants whose households were given placebo, with a calculated

incidence density of 0.159 infections/person-year (**Table 3**, **Figure 5**).[49] In contrast, 134 total

malaria attacks occurred in transfluthrin-active households with approximately 1079 person-

years at risk resulting in a calculated 0.124 infections/person-year. A cumulative 439 malaria

infections (first-time and subsequent) during approximately 1216 person-years at risk in

participants with households provided placebo, produced an incidence density of 0.361

infections/person-year. Contrastingly, 253 total (accumulative) malaria attacks occurred among

participants living in active intervention households with approximately 1216 person-years at

risk equaling 0.209 infections/person-year (**Table 3**).

Subgroup analyses of protective effect against malaria infection among non-zero incidence

and entomology clusters (not pre-planned).

Among the 24 clusters, there were five clusters with zero baseline incidence having had

zero to very low incidence rates during intervention. The first subgroup analysis used the 19

clusters with non-zero incidence rate as the remaining five clusters may have been excluded from

the intervention if baseline analysis had been performed before randomization. Excluding these

five clusters, the estimated PE for overall (total new) infections in the remaining subgroup of 19

clusters with non-zero baseline incidence rates was 40.9% (90% CI: 8.61, 61.8%) resulting in a

one-sided *p*-value of 0.0236 (**Table 3**). The second subgroup analyses included incidence from

the 12 clusters having routine entomology collection data (i.e., mean anopheline landing

rate/person), and where the average baseline incidence was approximately 4 folds greater than

the other study clusters. The PE using active intervention against time to first-event and overall

(total new) malaria infections in this subgroup was 55.3% (90% CI: 33.6, 69.9; *p*-value <0.0004)

and 66% (90% CI: 49.2%, 76.7%; *p*-value <0.0001), respectively (**Table 3**). The data indicate

the baseline covariates (subject, house construction, population and baseline malaria incidence)

between the active and placebo arms were balanced at the individual-, household-, and cluster-

level in the 19 non-zero incidence and 12 entomology cluster subgroup analyses (not shown).

Effects on entomological endpoints.

Results presented are summary outcomes on aggregated anopheline species captured

using HLC. Detailed data analyses on effects of this intervention on entomology measures is

forthcoming in subsequent publications, to include temporal change in species-specific

anopheline vector composition over the trial period, relative abundance between treatment arms

by species, and the HLC of non-anophelines (culicine mosquitoes).

Anopheline landing rates. A total of 52 weeks of HLC were performed within a subset of 12

clusters during the intervention period. Results based on morphological species identification

detected 19 putative malaria vector species showing spatial and temporal variation across

monitored clusters. The most common anopheline species (s.s. or s.l.) attracted to humans

included: *Anopheles aconitus*, *An. annularis*, *An. barbirostris*, *An. flavirostris*, *An. kochi*, *An.*

maculatus, *An. subpictus, An. sundaicus, An. tessellatus* and *An. vagus* (**S3. Anopheline**

Frequency Summary). The cumulative indoor (n=8,780) and outdoor (n=9,207) anopheline

landing rates across both baseline and intervention sampling periods are shown in **Figure 6**.

There was a numerical reduction in indoor and outdoor landing density from collections

performed in households provided active intervention (n= 3,883 and 4,373, respectively)

compared with placebo households (n= 4,897 and 4,834, respectively). The reduction in

anopheline attack rate on collectors positioned indoors and outdoors, at sentinel households with

active intervention compared with placebo houses was not statistically significant: 16.4% (95%

CI = -75.2%, 182.7%; p = 0.774) and 11.3% (95% CI = -73.7%, 199.4%; p =0.847), respectively

(**Table 4**).

Sporozoite positivity rate and Entomological Inoculation Rate (EIR). A total of 11,928 and

17,986 anopheline samples from baseline and intervention follow-up periods, respectively, were

processed for malaria sporozoites. The frequency of sporozoite positive anophelines is provided

in **Table 5.** Only *P. falciparum* and *P. vivax* infections were detected in captured mosquitoes.

During baseline and intervention period, the sporozoite rate was less than 0.5% for both

treatment and placebo arms. Data sparsity regarding comparison of sporozoite rates precluded

inferential statistical analyses. The EIR was <1 bite per year in both treatment arms during

baseline and intervention periods.

Parity rate (age-grading). A total of 15,828 anopheline samples were dissected for parity status

during the trial period (**Table 6**). The proportion of females categorized as "older," combining

parous and gravid states (mosquitoes with advanced ovarian follicle development as evidence of

a recent blood meal), and those "younger" as nulliparous (non-bloodfed) and more recently

emerged, were compared between active and placebo treatments for the 12 clusters with

entomological monitoring was conducted. Overall, transfluthrin-active emanators proportionally

increased nulliparity in the sampled anopheline populations compared to placebo for both indoor

and outdoor locations (**Table 6**).

Insecticide susceptibility. A total of 5,091 adult female anophelines (chemical and control

bioassays) were evaluated for susceptibility: 700 samples during baseline, 1,805 during

intervention and 2,586 post-intervention. *Anopheles vagus* was the most widely distributed and

tested anopheline (56%), followed by *An. sundaicus* (12.6%) and *An. subpictus*, *An. barbirostris*,

An. kochi, *An. aconitus*, *An. maculatus*, and *An. tessellatus* (proportionally, all < 10%). In the

CDC bottle bioassay, baseline, intervention and post-intervention tests using permethrin

(21.5ng/ml) showed 100% knockdown between 15-30 min exposure and within the

recommended diagnostic time. In the WHO tube bioassay with rare exception, there was 100%

24hr mortality to permethrin 0.75% following 60 min exposure. Based on the assumption of

predominately pyrethroid-susceptible wild populations of *Anopheles* species present in trial sites,

there was no conclusive evidence of the development of phenotypic resistance to pyrethroid class

chemicals between pre-and post-intervention periods. Interestingly, in several clusters during the

post-intervention phase, there were indications of reduced permethrin susceptibility (WHO

bioassay) in a few *An. barbirostris* populations to permethrin. Follow-up investigations provided

inconsistent results, thus confirmation that these focal populations showed low levels of

resistance could not be verified. The determination of presence or absence of target-site

mechanisms for resistance will be reported separately.

Adverse Events (AE) and Severe Adverse Events (SAE).

Using government clinic health records, a total of 523 AEs were reported from non-participants

while 144 AEs were reported from the intervention study cohort captured by the study team. Of

subject AEs, 52 were reported from participants in the active intervention arm and 92 from

placebo clusters. General respiratory complaints were most common for all reported AEs,

followed by general fever. There were 6 total SAEs reported in the overall study cohort during

follow-up: one death due to suspected brain infection; one death from respiratory infection; one

death from malaria with concomitant bacterial or viral infection; one death by drowning, and two

deaths of unknown cause.

Intervention Quality Control.

A total of 180 unused emanator samples were analyzed in 2017. Samples were taken from 12

different active and placebo clusters with manufacturing dates ranging from April to November

2016 (15mo to 8mo-old samples). All sampled placebo interventions (n = 48) were found to be

absent for transfluthrin. The average transfluthrin quantity from all sampled active emanators (n

= 132) was 54.3 mg, which was within the specification range (55.0 mg ± 2.75 mg).

DISCUSSION

Malaria remains a significant global public health burden despite recent progress in reducing

transmission rates.[50] The primary objective of this large-scale RCT conducted on Sumba Island,

Indonesia was to demonstrate and quantify the protective efficacy (PE) of a passive emanating

spatial repellent intervention (transfluthrin-treated), for reducing malaria incidence

(transmission) in humans. Such epidemiological evidence of health impact is a fundamental

requirement in the critical path of development of new vector control intervention classes being

assessed by the WHO VCAG.[16] Sumba Island, Indonesia was selected as the study site based on

WHO VCAG requirements of assessing evidence from varied endemic settings where spatial

repellents are intended to be implemented if/when a policy recommendation is endorsed. In

addition, Sumba does not currently conduct routine IRS and LLINs were only recently

distributed.

The primary per-protocol analyses provide an estimate of 27% PE against malaria

infection, which is near the efficacy of 30% selected in the power calculations. This effect,

however, was not statistically significant with confidence intervals that include zero. There were

298 first-time infections, in contrast to an expected number of at least 417 assumed in the sample

size calculations, thus resulting on the trial being underpowered. The demonstration of spatial

repellency PE (66%) against total new infections in the subset of 12 clusters used for

entomological measures, which had approximately 4 folds greater malaria infection incidence

during intervention, indicates health impact where risk of malaria infection was greatest (i.e.,

locations with highest vector landing densities). Outcomes reported here are promising for

malaria control, despite the study being unable to demonstrate clear, statistically protective

efficacy on primary analysis, with data anticipated to be included in meta-analyses with other

clinical trials evaluating spatial repellents.

This study highlights three primary challenges for consideration in future spatial repellent

trials as well for new vector control intervention classes more broadly: 1) firstly, having

'adaptive' study designs, especially for evaluation of interventions in low to moderate malaria

transmission settings and/or settings with inherently large cluster-to-cluster variance on

transmission intensity; 2) defining and identification of the 'key' entomological correlates of

protection; and 3) ensuring reliability and feasibility in AE/SAE reporting for accurate safety

assessment. Regarding adaptive study designs, our assumptions for power and sample size

calculations were based on a previous proof-of-concept study that took place in an entirely

coastal location but was spatially very near (bordering) the current study area.[19] The study

villages, both coastal and further inland, were selected with the assumption that all clusters

delineated from these villages would experience similar levels of malaria transmission during the

intervention period; however, this was not the case during the trial. As in all epidemiological

trials, underlying assumptions of incidence used for power and sample size calculations can vary

from actual incidence during intervention follow-up. Baseline data analyses indicated zero-

incidence for five of the 24 selected study clusters with a 5-folds higher between-cluster

variability than assumed in the original sample size calculation. The five clusters with zero

baseline incidence (two allocated to receive active and three allocated to receive placebo) also

had either zero or low incidence rates during intervention and ranked in the top 8 among the 24

clusters in terms of lowest in intervention incidence (data not shown).

577   In retrospect, a pre-planned interim and final analysis of the baseline data would have

allowed for consideration in adjustment of the study design by filtering out the zero-incidence

clusters, or increasing the study duration (time of follow-up), the number of subjects recruited

per cluster, or the number of clusters to better satisfy requirements of statistical power and

capture the necessary number of outcome events (infections). However, baseline incidence was

measured only for verifying hierarchical stratification and use as a covariate in statistical

analyses of PE. This therefore, resulted in: 1) the original sample size not accommodating for

interim and final analyses of baseline data; 2) timelines of grant period not being projected and

assured to include lag-time for baseline data analyses and outcome assessment; and perhaps most

importantly 3) baseline incidence analyses not being explored early to determine variations in

sample size /cluster number adjustments required to achieve sufficient study power and

subsequent study site viability.

Given the updated baseline incidence rate of 0.131 per person-year and 97.1% CV, to

maintain 80% power with the originally assumed 30% PE, 100 clusters per arm with 144

households (HHs; i.e. subjects) would have been required to be recruited to collect 5,550 first-

time malaria events – an unmanageable scale that could not have been supported due to

geographical, logistical and funding constraints. Moreover, increasing the follow-up time to

collect more first-time malaria events would have neither counterbalanced the large variability

nor the longer duration required to collect the additional events due to the seasonally-influenced

low to moderate malaria transmission among clusters. For this reason, when planning future

trials in low or moderate endemic settings, investigators should consider including a greater

number of clusters per arm and/or building into the statistical analyses plan an interim and final

analyses of *baseline* incidence with pre-determined study design adaptations, to include down-

selection of clusters with predetermined incidence thresholds. This may become most relevant

when considering proof of efficacy of an intervention in low transmission settings as a

component for malaria elimination goals. Early exercises of the impact of a lower than assumed

incidence (or greater CV) during study planning should be explored amongst investigators,

industry and funding partners to ensure that the study area context, intervention manufacturing,

program period and/or funding can sufficiently meet the demands of power requirements if

adjustments are to be made once the study begins. Stakeholders should also discuss supporting

and adopting adaptive designs thereby allow decision-making after planned interim analysis of

intervention data, to either stop the trial for futility or to continue the trial with adjusted design

parameters, such as sample size.[51, 52] Perhaps just as important in the context of vector control,

although RCTs are rated as high-quality evidence,[53] considerations to RCT alternatives are

prudent in the trial planning phase as these may offer assurances of adequate data rigor while

balancing cost and time constraints of traditional RCTs.[54, 55] Alternative study designs include

large observational studies for detecting population-level effects using analytical cross-sectional

studies, or operational program-based evidence; the latter perhaps especially for interventions

containing an existing registered chemical active ingredient (i.e., meets human safety thresholds)

and where the intervention is implemented in pilot trials and impact monitored through case

reports, as compared to a contemporaneous control group.[55]

Albeit the study was not powered for entomology, the inclusion of entomological

endpoints in the Sumba RCT was, in part, to help understand and validate the intervention's

mode of action for the VCAG claim of a health impact through a reduction in human-vector

contact. Spatial repellent chemicals may cause initial knockdown and mortality by exposure to

toxic doses at close range to the active ingredient, or a delayed kill through behavioral avoidance

response (i.e., blood-feeding inhibition), through exposure to sub-lethal doses at distances further

away from the stimulus source. Therefore, entomological measurements for detecting reductions

in human-landing density in clusters with active intervention, and a possible change in

anopheline age structure (parity rate) indicating older populations not surviving as long as in

placebo areas, was built into this study. Additionally, a reduction in sporozoite infection rates,

because of lower blood feeding success, and/or an inability to survive the required time interval

(parasite incubation period) to become infective (transmissible) from a vector to a host, represent

other endpoint measures of repellency impact. A causal relationship with one, several or all, of

these endpoints would allow future trials evaluating non-inferiority of a 'second-in-class' spatial

repellent to integrate entomological measures only to predict PE and provide assurances of

meeting minimum thresholds of acceptance for public health use.

Sporozoite positivity rates and EIR estimates from the current trial were low, with a total

of 42 of 11,650 (0.36%) anophelines tested during baseline (10mo) and 19 of 17,971 (0.11%)

found infected during intervention (24mo). These findings are not unusual or unexpected in low

to moderate malaria transmission settings.[28] As example, the previous Sumba study (using

metofluthrin coils) reported just 15 out of 1,825 (0.82%) HLC anopheline samples sporozoite

infected.[19] The challenges for assessing sporozoite infectivity and using EIR as a measure of

intervention effect in such settings should be factored into study pre-planning to carefully

balance cost of sample processing with potential useful information gained.

These study findings report a 16.4% numerical reduction in indoor-landing mosquitoes

exposed to active treatment compared to placebo-control. Just as important was an observed

numerical reduction (11%) on outdoor-landing collections on the exposed verandah of sentinel

houses, as Sumba residents often sleep on the verandah without the protection of a bed net. It is

noted, however, that both indoor and outdoor HLC outcomes showed wide CIs that overlap zero,

making results inconclusive. A previous proof-of-concept study on Sumba that evaluated a

metofluthrin-active coil resulted in a significant 32% reduction in *An. sundaicus* indoor landing

rates as compared to a blank-coil control;[19] The minimal reduction in the human landing rate in

the current RCT may be the result of species-specific effects by active ingredient (i.e.,

metofluthrin vs. transfluthrin) but differences in HLC outcomes of the two studies on Sumba

should not be interpreted as the transfluthrin intervention being less efficacious than a coil. The

greater complexity of anopheline diversity may likely have contributed to the inconclusive HLC

outcomes based on aggregated anopheline data. It is expected similar results may occur in future

trials that are conducted in settings with diverse vector populations and/or as cluster size

increases thereby increasing the probability of greater habitat diversity.

Specifically, the previous Sumba study was smaller in scale and *An. sundaicus* was the

overwhelmingly predominate human-feeding anopheline collected; whereas in the current study

this species was relatively uncommon during the intervention trial. The range of ecologies

(coastal plains to upland forested hills) varied greatly across the 12 clusters used for entomology

collections in this trial compared to that of the earlier Sumba study where collections were

confined to only 4 adjoining clusters having similar coastal environments. This spatial variability

in ecology contributed to a broader range of species diversity. We report 19 species/group

species identified), each species with different bionomic and behavioral characteristics (e.g.,

biting habits, host preferences). Perhaps most important, the efficacy of an intervention is related

to epidemiological outcomes (reduced risk of infection); HLC outcomes reported from the

current study were inconclusive, but nevertheless showed impact against malaria.

Insecticide susceptibility monitoring was integrated into the study to characterize the

wild-type anopheline populations to estimate PE against resistant vector populations, if

resistance was expressed, and monitor changes in susceptibility due to continuous exposure to

transfluthrin. Our data indicates that continual use of transfluthrin as a spatial repellent during a

consecutive 24-mo period did not result in a change in phenotypic response to permethrin.

Although we are confident in the findings presented, there were limitations in sampling from

multiple sites and handling numerous species during pre-, within, and post-intervention periods.

This may have compromised the study's ability to obtain a more robust and definitive profile of

susceptibility background and detection of any shift in phenotypic (and molecular) frequencies.

The third 'lesson-learned' from the current study relates to AE and SAE monitoring.

Reports of intervention safety in this study should take into account possible limitations of the

data collection. The DSMB was provided with clinic attendance data from January 2015 to

December 2018, for upper respiratory infection (URI), pneumonia, and malaria, as classified by

month, health center, and village within health center coverage. Although not gathered as part of

the study, the DSMB was keenly interested in these data because of the surprisingly low number

of illnesses/deaths reported from the study population during the 24-month intervention period.

For some periods, particularly for malaria infection, the case data were missing or the health

center totals were not available at the village level. Of the 13 villages represented in the dataset,

from which study clusters were formed, all but four comprised clusters (or parts of clusters) from

both study intervention arms (i.e., allocated active or placebo); therefore, it was not possible to

infer the allocation status of the corresponding cases. For this reason, the DSMB was unable to

make a reliable assessment of any possible association between active intervention and clinic

attendance for those reported health conditions. The respiratory illnesses in the clinic data are

more reflective of the magnitude of numbers of cases one would expect from this population;

however, the DSMB was again unable to parse them into test and control clusters due to reasons

stated above, and therefore the data was of little use for monitoring purposes. The number of

SAEs reported, a total of six, is well below the expected in a study population of this size. The

WHO estimates the crude death rate in Indonesia to be approximately 6.2 per thousand per

year.[56] Based on this, for a population of 1,296 children enrolled (protocol sample size), the

probability of having zero deaths in a year is less than one in 1,000. Although open

commemoration of deaths is commonly practiced in the study area, it seems more likely deaths

were not completely reported/recorded as SAEs.

Overall, the point to apply for future spatial repellent trials (and perhaps other trials of

new vector control interventions) is to improve the mechanism for capturing and communicating

AEs and SAEs before the initiation of the study to better ensure reliable reporting and regular

monitoring for unusual numbers of complaints. If these studies are regarded as a clinical trial

with a placebo arm that requires comparative AE and SAE data, the scale could cause failure in

safety assessment simply on the mass of data, however imperfectly collected. Any safety signal

detected would most likely be due to bias in reporting and/or collection bias and unrelated with

the investigational intervention. Trials evaluating a spatial repellent intervention with a registered

active ingredient (i.e., a chemical meeting regulatory approvals for acceptable levels of human

risk) such as transfluthrin, could focus on a small number of complaints that might be expected

due to inhalation (i.e., volatilization) and develop a monitoring scheme that collects consistent

data across the study population. Clinic-based complaints of respiratory illness such as

pneumonia and asthma might be possible, but the variability in their method of collection (clinic

or survey) will likely be highly dependent on study site infrastructure.

In conclusion, while more evidence will be required to determine whether spatial

repellents can serve as a viable malaria control intervention, both the primary and secondary

results of this Sumba Island trial have generated valuable data and observations that can

contribute to the overall assessment and improvement of testing protocols of a spatial repellent

intervention class. The VCAG has recommended that data from at least one additional trial

evaluating the spatial repellent be generated,[57] and once available, the panel will be able to assess

the available evidence for judging public health value. If the crude estimate of PE shown here,

near 30%, is replicated in future statistically robust cluster-randomized trials, the intervention

prototype evaluated in this RCT would approximate the benefit associated with LLINs.[58] Perhaps

just as important, the difference in the overall (total new) infection rate between transfluthrin-

active and placebo-control, i.e., the number of cases averted, indicates 361 expected cases per

1000 persons per year (0.361*1000*1) without the spatial repellent and 152 less cases expected

when using the active intervention ((0.361-0.209)*1000*1). The cost-savings of averting these

152 less cases per 1000 person-years is an important consideration for health-systems

strengthening. These results have encouraged further and substantial investment to validate

spatial repellent efficacy through larger RCTs, including an investigation of possible vector

diversionary effects on human health (i.e., greater than expected malaria incidence in households

near intervention not receiving active product), and evaluation of the optimal delivery systems

for humanitarian assistance use-case scenarios.[59]

Acknowledgments: We extend sincere appreciation to DSMB members: Dennis Shanks, Chris

Drakeley, and Neal Alexander for assurances on data integrity and safety assessments. We also

express our gratitude to fhi360 partners Kathy Bowerman, Ahmed Goolam and Zen Hafy for

trial oversight and monitoring of protocol compliance. We thank the WHO VCAG for their

comments from recurrent project data assessments. We are grateful for the tireless efforts of

Wirda Damanik, study administrator at the Eijkman Institute for Molecular Biology in Jakarta,

and Marianne Kent, Program Coordinator at the University of Notre Dame, for their expert

administrative, logistical, and financial management support of this endeavor. We thank Julie

Neidbalski, Katie Cybulski, Diane Lovin, Joanne Cunningham, Jenna Davidson, and Allison

Hendershot at the University of Notre Dame for their contribution to human blood and mosquito

sample quality control processing as well as David Pettifor of the University of Notre Dame

Center for Research Computing for assisting with central database development and data

verification. We gratefully thank the residents in the study area for their time and patience

participating in this trial. Special gratitude is extended to the Southwest and West Sumba

Districts Health Department for their kind support, the parasitology and entomology teams, local

field workers, data entry clerks, and the numerous local volunteers for their long-serving

dedication to quality of data and meeting the project objectives.

Financial support: This study was funded by a substantial award from the Bill and Melinda

Gates Foundation (BMGF) to the University of Notre Dame (Grant# OPP1081737). We express

our gratitude to the Foundation for their long-term generosity and support of spatial repellent

product evaluation and development, especially Kate Aultman, Dan Strickman and Alan Magill.

We are also deeply grateful to SC Johnson for its financial support. The company provided

integral industry and product expertise including the development, manufacturing, delivery and

shipment of the intervention (active and placebo) used in the study. Additionally, SC Johnson

provided expertise in ensuring intervention quality, storage, application and disposal assurances

throughout the trial.

Disclaimer: The contents are the responsibility of the authors.

765   REFERENCES

1. Kennedy JS, 1947. The Excitant and Repellent Effects on Mosquitos of Sub-lethal Contacts
with DDT. *Bull Entomol Res 37:* 593-607.

2. Muirhead-Thomson RC, 1951. Mosquito Behaviour in relation to Malaria Transmission and
Control in the Tropics. London: Edward Arnold & Co., 219.

3. De Zulueta J, Cullen JR, Smith A, 1963. Deterrent Effect of Insecticides on Malaria Vectors
. *Nature 200:* 860-862.

4. Dethier VG, Browne BL, Smith CN, 1960. The Designation of Chemicals in Terms of the
Responses They Elicit from Insects. *J Econ Entomol 53:* 134-136.

5. Miller JR, Siegert PY, Amimo FA, Walker ED, 2009. Designation of Chemicals in Terms of
the Locomotor Responses they Elicit from Insects: an Update of Dethier et al. (1960). *J Econ
Entomol 102:* 2056-2060.

6. Roberts DR, Alecrim WD, Hshieh P, Grieco JP, Bangs M, Andre RG, Chareonviriphap T,
2000. A Probability Model of Vector Behavior: Effects of DDT Repellency, Irritancy, and
Toxicity in Malaria Control. *J Vector Ecol 25:* 48-61.

7. WHO Pesticide Evaluation Scheme, 2013. Guidelines for Efficacy Testing of Spatial
Repellents. Geneva: World Health Organization.

8. Grieco JP, Achee NL, Sardelis MR, Chauhan KR, Roberts DR, 2005. A Novel High-
Throughput Screening System to Evaluate the Behavioral Response of Adult Mosquitoes to
Chemicals. *J Am Mosq Control Assoc 21:* 404-411.

9. Achee NL, Sardelis MR, Dusfour I, Chauhan KR, Grieco JP, 2009. Characterization of Spatial
Repellent, Contact Irritant, and Toxicant Chemical Actions of Standard Vector Control
Compounds. *J Am Mosq Control Assoc 25:* 156-167.

10. Ogoma SB, Ngonyani H, Simfukwe ET, Mseka A, Moore J, Maia MF, Moore SJ, Lorenz
LM, 2014. The Mode of Action of Spatial Repellents and Their Impact on Vectorial Capacity of
Anopheles gambiae sensu stricto. *PLoS ONE 9:* e110433.

11. Ogoma SB, et al, 2014. An Experimental Hut Study to Quantify the Effect of DDT and
Airborne Pyrethroids on Entomological Parameters of Malaria Transmission. *Malar J 13:* 131.

12. Grieco JP, Achee NL, Chareonviriyaphap T, Suwonkerd W, Chauhan K, Sardelis MR,
Roberts DR, 2007. A New Classification System for the Actions of IRS Chemicals Traditionally
Used For Malaria Control. *PLoS One 2:* e716.

13. U.S EPA Office of Pesticide Programs, 2018. Conventional New Chemical Registration
Decisions - Completed FY 2018.

14. Norris E, Coats J, 2017. Current and Future Repellent Technologies: The Potential of Spatial
Repellents and Their Place in Mosquito-Borne Disease Control. *International Journal of*
Environmental Research and Public Health 14: 124.

15. Debboun M, Frances SP, Strickman D, 2006. Insect Repellents: Principles, Methods, and
Uses. Boca Raton, FL: CRC Press, 495.

16. WHO, 2017. The Evaluation Process for Vector Control Products. *WHO.* Geneva: World
Health Organization.

17. Maia MF, Kliner M, Richardson M, Lengeler C, Moore SJ, 2018. Mosquito Repellents for
Malaria Prevention. Available at: /CD011595/INFECTN_mosquito-repellents-malaria-
prevention. Accessed Oct 24, 2019.

18. Hill N, Zhou HN, Wang P, Guo X, Carneiro I, Moore SJ, 2014. A Household Randomized,
Controlled Trial of the Efficacy of 0.03% Transfluthrin Coils Alone and in Combination with
Long-Lasting Insecticidal Nets on the Incidence of *Plasmodium falciparum* and *Plasmodium*
vivax Malaria in Western Yunnan Province, China. *Malar J 13:* 208.

19. Syafruddin D, et al, 2014. Impact of a Spatial Repellent on Malaria Incidence in Two
Villages in Sumba, Indonesia. *Am J Trop Med Hyg 91:* 1079-1087.

20. WHO-Department of Control of Neglected Tropical Diseases, 2017. How to Design Vector
Control Efficacy Trials. Guidance on Phase III Vector Control Field Trial Design. *WHO.*
Geneva: World Health Organization. 62.

21. Ogoma SB, Moore SJ, Maia MF, 2012. A Systematic Review of Mosquito Coils and Passive
Emanators: Defining Recommendations for Spatial Repellency Testing Methodologies. *Parasit*
Vectors 5: 287.

22. Achee NL, Grieco JP, 2012. Is It Time to Formally Recognize Spatial Repellency for Disease
Prevention? *Outlooks on Pest Management 23:* 283-286.

23. Achee NL, et al, 2012. Spatial Repellents: from Discovery and Development to Evidence-
Based Validation. *Malar J 11:* 164.

24. Hemingway J, Shretta R, Wells TNC, Bell D, Djimdé AA, Achee N, Qi G, 2016. Tools and
Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand
Convergence in Malaria? *PLoS Biol 14:* e1002380.

25. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research,
2018. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). *FDA.* Silver Spring,
MD: US Food and Drug Administration.

26. OECD, OECD Series on Principles of Good Laboratory Practice (GLP) and Compliance
Monitoring. Available at:

http://www.oecd.org/chemicalsafety/testing/oecdseriesonprinciplesofgoodlaboratorypracticeglpa
ndcompliancemonitoring.htm.

27. Badan Pusat Statistik, 2010 Population Census - Indonesia. Available at:
http://sp2010.bps.go.id/. Accessed Jul 10, 2019.

28. Elyazar IRF, Sinka ME, Gething PW, Tarmidzi SN, Surya A, Kusriastuti R, Winarno, Baird
JK, Hay SI, Bangs MJ, 2013. The Distribution and Bionomics of Anopheles Malaria Vector
Mosquitoes in Indonesia. D. Rollinson, ed. Advances in Parasitology. Amsterdam: Elsevier Ltd.,
173-266.

29. Barbara KA, Sukowati S, Rusmiarto S, Susapto D, Bangs MJ, Kinzer MH, 2011. Survey of
Anopheles Mosquitoes (Diptera:Culicidae) in West Sumba District, Indonesia. *Southeast Asian J*
Trop Med Public Health 42: 71-82.

30. Lievens M, Aponte JJ, Williamson J, Mmbando B, Mohamed A, Bejon P, Leach A, 2011.
Statistical Methodology for the Evaluation of Vaccine Efficacy in a Phase III Multi-centre Trial
of the RTS, S/AS01 Malaria Vaccine in African Children. *Malar J 10:* 222.

31. LaRue N, et al, 2014. Comparison of Quantitative and Qualitative Tests for Glucose-6-
Phosphate Dehydrogenase Deficiency. *Am J Trop Med Hyg 91:* 854-861.

32. Bernard Nkrumah, Samuel Blay Nguah, Nimako Sarpong, Denise Dekker, Ali Idriss, Juergen
May and Yaw Adu-Sarkodie, 2011. Hemoglobin Estimation by the HemoCue® Portable
Hemoglobin Photometer in a Resource Poor Setting. *BMC Clinical Pathology 11:*.

33. WHO Specifications and Evaluations for Public Health Pesticides, 2016. Transfluthrin.
World Health Organization. Geneva: WHO.

34. United States Environmental Protection Agency, 2018. Registration Decision for the New
Active Ingredient, Transfluthrin. Washington, DC: US EPA.

35. Echeverry DF, et al, 2016. Human Malaria Diagnosis Using a Single-step Direct-PCR Based
on the *Plasmodium* cytochrome oxidase III gene. *Malar J 15:* 128.

36. World Health Organization & UNICEF/UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases, 2015. Microscopy for the Detection, Identification
and Quantification of Malaria Parasites on Stained Thick and Thin Blood Films in Research
Settings. *World Health Organization.* 33.

37. O'Connors CT, Soepanto A, 1979. Kunci kunci bergambar untuk Anopheles betina dari
Indonesia. Translated and revised by Atmosoedjono S, Bangs, MJ, 1989. Illustrated key to the
Anopheles of Indonesia. 1989. Jakarta, Indonesia: The Ministry of Health. 1-40.

38. Detinova TS, 1962. Age-grouping Methods in Diptera of Medical Importance with Special
Reference to some Vectors of Malaria. *Monogr Ser World Health Organ 47:* 13-191.

39. Lobo NF, et al, 2015. Unexpected Diversity of *Anopheles* Species in Eastern Zambia:
Implications for Evaluating Vector Behavior and Interventions using Molecular Tools. *Sci Rep*
5: 17952.

40. St Laurent B, et al, 2016. Behaviour and Molecular Identification of *Anopheles* Malaria
Vectors in Jayapura District, Papua Province, Indonesia. *Malar J 15:* 192.

41. Echeverry DF, et al, 2017. Fast and Robust Single PCR for *Plasmodium* sporozoite Detection
in Mosquitoes using the Cytochrome Oxidase I Gene. *Malar J 16:* 230.

42. Beier JC, 2002. Vector Incrimination and Entomological Inoculation Rates. *Methods Mol*
Med 72: 3-11.

43. WHO, 2016. Test Procedures for Insecticide Resistance Monitoring in Malaria Vector
Mosquitoes (Second edition). Geneva: World Health Organization.

44. Center for Disease Control and Prevention, 2010. Guideline for Evaluating Insecticide
Resistance in Vectors Using the CDC Bottle Bioassay. Atlanta: The Centers.

45. John D. Kalbfleisch, Ross L. Prentice, 2002. The Statistical Analysis of Failure Time Data.
John Wiley and Sons, 462.

46. Paul D. Allison, 1982. Discrete-Time Methods for the Analysis of Event Histories.
Sociological Methodology 13: 61-98.

47. David Collett, 2002. Modelling Binary Data. London: Chapman and Hall/CRC, 408.

48. Redmond, C. and Colton, T., ed., 2001. Biostatistics in Clinical Trials. John Wiley & Sons.

49. Baird JK, Bangs MJ, Maguire JD, Barcus MJ, 2002. Epidemiological Measures of Risk of
Malaria. *Methods Mol Med 72:* 13-22.

50. World Health Organization, 2018. World Malaria Report 2018. *WHO.* World Health
Organization.

51. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD, 2009.
Adaptive Designs for Randomized Trials in Public Health. *Annu Rev Public Health 30:* 1-25.

52. Shein-Chung Chow, Mark Chang, 2011. Adaptive Design Methods in Clinical Trials.
London: Chapman and Hall/CRC Biostatistics Series, 375.

53. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ,
2008. GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of
Recommendations. *BMJ 336:* 924-926.

54. Frieden TR, 2017. Evidence for Health Decision Making - Beyond Randomized, Controlled
Trials. *N Engl J Med 377:* 465-475.

55. Wilson AL, Boelaert M, Kleinschmidt I, Pinder M, Scott TW, Tusting LS, Lindsay SW,
2015. Evidence-based Vector Control? Improving the Quality of Vector Control Trials. *Trends*
Parasitol 31: 380-390.

56. WHO-Global Health Observatory Data Repository, 2015. Crude Birth and Death Rate
Data by Country. Available at: http://apps.who.int/gho/data/view.main.CBDR2040. Accessed
07/08/2019.

57. VCAG, Vector Control Advisory Group. Available at: http://www.who.int/vector-
control/vcag/en/. Accessed Jul 10, 2019.

58. Lengeler C, 2004. Insecticide-treated Bed Nets and Curtains for Preventing Malaria.
Cochrane Database Syst Rev CD000363.

59. Unitaid, Innovative Repellents for Disease-carrying Mosquitoes. Available at:
https://unitaid.org/project/innovative-repellents-for-disease-carrying-mosquitoes/. Accessed Jul
10, 2019.

TABLES

Table 1. Malaria infection prevalence data from 10 months before randomization in the 13 villages from which study clusters were delineated on Sumba Island.

Village	Number of samples	Number of malaria infections	Slide Positive (%)
Matakapore	806	110	13.65
Manutoghi	622	217	34.88
Waimakaha	621	149	23.99
Wailangira	857	52	6.07
Waikarara	1,420	63	4.44
Panenggo Ede	610	15	2.46
Waimaringi	649	67	10.32
Tana Mete	810	81	10.00
Kahale	903	202	22.37
Rada Malando	402	150	37.31
Karang Indah	523	195	37.28
Gaura	1,297	165	12.70
Weetana	1,129	163	14.40

Table 2. Summary baseline covariates for both spatial repellent (SR) and placebo treatment arms for the primary analysis.

Individual level		
	SR (n = 665)	**Placebo (n = 667)**
Age in months (mean ± SD, (min, max))	34.0 ± 15.1 (6, 59)	34.2 ± 14.8 (6, 59)
Gender (% male subjects)	54.1%	51.1%
Household level		
	SR (n = 665)	**Placebo (n = 667)**
House wall type (wood %)	91.6%	94.0%
Open eaves (yes %)	98.0%	99.6%
No. of doors (mean ± SD, (min, max))	2.06 ± 0.38 (1, 4)	2.06 ± 0.30 (0, 4)
Cluster level		
	SR (n = 12)	**Placebo (n = 12)**
Cluster population (mean ± SD, (min, max))	694.3 ± 59.2 (624, 820)	730.8 ± 129.0 (616,1117)
Baseline incidence rate per person-year (mean ± SD, (min, max))	0.096 ± 0.115 (0, 0.426)	0.089 ± 0.088 (0, 0.265)
Baseline overall (total new) infection incidence per person-year (mean ± SD, (min, max))	0.094 ± 0.111 (0, 0.412)	0.089 ± 0.087 (0, 0.261)

Table 3. Summary first-time and overall (total new) malaria incidence during study.

	First-time infection			Overall (total new) infections		
	All clusters	**Subgroup 1[#]**	**Subgroup 2[*]**	**All clusters**	**Subgroup 1[#]**	**Subgroup 2[*]**
	SR : Placebo					
No. of clusters	12:12	10:9	6:6	12:12	10:9	6:6
No. of households	665 : 667	557 : 500	335 : 335	665 : 667	557 : 500	335 : 335
No. of infections	134 : 164	130 : 158	93 : 140	253 : 439	249 : 433	196 : 408
Person years	1079 : 1032	873 : 722	506 : 444	1216 : 1216	1015 : 909	609 : 607
Incidence rate (per person-year)	0.124 : 0.159	0.149 : 0.219	0.184 : 0.315	0.208 : 0.361	0.245 : 0.476	0.322 : 0.672
Hazard Ratio (90% CI)	0.723 (0.431,1.213)	0.64 (0.299, 1.367)	0.447 (0.302, 0.664)	0.687 (0.426,1.108)	0.591 (0.382, 0.914)	0.344 (0.233, 0.508)
PE (%) (90% CI)	27.7 (-21.3, 56.9)	33.3 (-7.8, 58.7)	55.3 (33.6, 69.9)	31.3 (-10.8, 57.4)	40.9 (8.61, 61.8)	65.6 (49.2, 76.7)
1-sided *p*-value	0.151	0.083	0.0004	0.098	0.0236	<0.0001

[#] Subgroup 1: clusters with non-zero incidence during intervention
[*] Subgroup 2: clusters with entomology data collected (moderate-to-high risk of infection)

Table 4: Intervention effect on anopheline mosquito landing rates by collection location.

Location[1]	SR (mean ± SD) [2]	Placebo (mean ± SD)	% Change (95% CI) SR vs. Placebo	*p*-value
Indoor	3.14 ± 5.84	3.97 ± 8.73	-16.4 (-75.2, 182.7)	0.774
Outdoor	3.54 ± 7.13	3.93 ± 8.64	-11.3 (-73.7, 199.4)	0.847
[1] Position at each human landing catch (HLC) sentinel house where sample was captured (indoor = near center of house; outdoor = on verandah ~1m from edge of exterior wall. [2] Human landing rate based on 12-hour collection per person.				

Table 5. Frequency of anopheline (all species) sporozoite infection status for both spatial repellent (SR) and placebo treatment arms.

Treatment Allocation	Pf[1]	Pv[2]	Indeterminate[3]	Non-infected	Sporozoite Positivity Rate[4]
Baseline					
SR	12	9	0	4706	0.44%
Placebo	12	9	0	6244	0.34%
Intervention					
SR	3	8	0	8130	0.14%
Placebo	6	1	1	9615	0.07%
[1]Pf = *Plasmodium falciparum* [2]Pv= *Plasmodium vivax* [3]Indeterminate defined as *Plasmodium* positive sample but parasite species not identifiable [4]Sporozoite positivity rate = [(Pf + Pv) / (Pf + Pv + Indeterminate + non-infected)] x 100%					

Table 6. Spatial repellent (SR) intervention effect on parity and nulliparity rates (all anopheline species).

	HLC Location[1]	SR (mean ± SD)[2]	Placebo (mean ± SD)	% Change (95% CI) SR vs. Placebo	2-sided *p*-value
Parous	Indoor (n=5,784)	0.41 ± 0.44 (n=2,537)	0.41 ± 0.45 (n=3,247)	-10.2 (-62.1, 113.2)	0.808
	Outdoor (n=6,193)	0.40 ± 0.44 (n=2,907)	0.43 ± 0.45 (n=3,286)	-25.9 (-68.8, 75.6)	0.495
Nulliparous	Indoor (n=1,873)	0.16 ± 0.29 (n=994)	0.12 ± 0.26 (n=879)	58.3 (-37.0, 298.0)	0.329
	Outdoor (n=1,978)	0.17 ± 0.30 (n=1,126)	0.11 ± 0.25 (n=852)	54.9 (-37.6, 284.3)	0.346

[1] Position of collector conducting human landing catch (HLC) (indoor = near center of house; outdoor = on house verandah ~1m from edge of exterior wall).
[2] Mean and SD are descriptive statistics; and % change was obtained from fitting negative binomial models.

FIGURES

Figure 1. Study site areas in Southwest and West Sumba districts located in Kodi, Kodi Bangedo and Lamboya sub-districts of Sumba Island, Nusa Tenggara Timur Province (eastern Lesser Sunda islands), Indonesia (map not to scale).

Figure 2. Traditional Sumba house structure (A) raised ~1m above ground and averaging ~70 m³ in size with thatch roof, bamboo floors and walls (B), which offer minimal protection from mosquito entry.

Figure 3. Location of 24 study clusters in West and Southwest districts, Sumba. Clusters were selected for enrolling the incidence cohort, each consisted of ca. 100 households with an average distance of 500m between clusters. A total of 48 sentinel houses from 12 clusters were selected for routine entomological human landing catch (HLC).

Figure 4. Flowchart of enrollment of study volunteers.

Figure 5: Cumulative incidence of time to first-infection for each of the 24 study clusters (spatial repellent (SR) intervention and placebo treatment arm).

Figure 6. Mean (+ SD) cumulative biweekly indoor (A) and outdoor (B) anopheline human landing catch (HLC) averaged over 20 to 24 households per treatment arm - spatial repellent (SR) intervention and placebo, respectively.